Cantor Fitzgerald Weighs in on Organogenesis FY2026 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Organogenesis in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of $0.16 per share for the year. The consensus estimate for Organogenesis' current full-year earnings is ($0.07) per share.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The business had revenue of $86.69 million for the quarter, compared to analysts' expectations of $90.77 million.

Separately, Morgan Stanley upped their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Trading Down 2.5%

NASDAQ:ORGO traded down $0.08 during trading hours on Wednesday, reaching $3.17. The company's stock had a trading volume of 898,194 shares, compared to its average volume of 1,157,912. The firm has a 50-day simple moving average of $3.77 and a 200-day simple moving average of $3.83. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis has a 1 year low of $2.28 and a 1 year high of $6.71. The firm has a market capitalization of $402.13 million, a price-to-earnings ratio of -52.83 and a beta of 1.63.

Hedge Funds Weigh In On Organogenesis

Several hedge funds and other institutional investors have recently modified their holdings of ORGO. Wells Fargo & Company MN increased its holdings in Organogenesis by 29.6% during the fourth quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after buying an additional 9,464 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Organogenesis by 18.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock valued at $8,925,000 after acquiring an additional 442,772 shares during the period. Prudential Financial Inc. increased its stake in shares of Organogenesis by 92.9% in the 4th quarter. Prudential Financial Inc. now owns 237,720 shares of the company's stock worth $761,000 after purchasing an additional 114,500 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of Organogenesis by 53.2% in the 4th quarter. Squarepoint Ops LLC now owns 126,791 shares of the company's stock worth $406,000 after purchasing an additional 44,051 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Organogenesis by 255.1% in the 4th quarter. Mackenzie Financial Corp now owns 76,353 shares of the company's stock worth $244,000 after purchasing an additional 54,850 shares during the period. 49.57% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Lori Freedman bought 142,379 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were purchased at an average price of $2.91 per share, for a total transaction of $414,322.89. Following the completion of the purchase, the insider now owns 837,437 shares in the company, valued at approximately $2,436,941.67. This represents a 20.48% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have purchased 252,264 shares of company stock worth $725,732 in the last 90 days. Insiders own 33.00% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.